Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
Source: View publication →
In patients with previously treated advanced KRAS G12C-mutated NSCLC, the next-generation inhibitor divarasib significantly prolonged progression-free and overall survival compared with first-generation inhibitors sotorasib or adagrasib.
Key Findings
Study Design
Study Limitations
Clinical Significance
The Krascendo 1 trial establishes divarasib as a new standard of care for previously treated KRAS G12C-mutated advanced NSCLC. By achieving a 44% reduction in the risk of death and a median overall survival of nearly 18 months, divarasib provides a highly clinically meaningful survival benefit over first-generation KRAS inhibitors, overcoming their historical limitations.
Historical Context
The KRAS G12C mutation is found in roughly 12-14% of NSCLCs. Sotorasib and adagrasib were the first targeted inhibitors to validate this once-undruggable target, receiving accelerated approvals based on early-phase data. However, in subsequent randomized phase 3 trials, these first-generation agents demonstrated limited progression-free survival benefits and failed to convincingly establish an overall survival advantage against docetaxel chemotherapy. Divarasib was engineered as a highly potent next-generation inhibitor. The Krascendo 1 trial marks the first randomized head-to-head phase 3 trial comparing a next-generation KRAS G12C inhibitor to first-generation inhibitors, definitively demonstrating that improved drug potency and selectivity can translate into superior overall survival in the clinic.
Guided Discussion
High-yield insights from every perspective
How does the specific amino acid substitution in the KRAS G12C mutation allow for the mechanism of action of covalent inhibitors like sotorasib, adagrasib, and divarasib, and why can these drugs not be used for other KRAS mutations like G12D?
Key Response
The G12C mutation replaces a glycine residue with a reactive cysteine. These targeted inhibitors are specifically designed to covalently bind to the thiol group of this mutant cysteine in the switch II pocket when KRAS is in its inactive, GDP-bound state, locking it off. Other mutations like G12D lack this reactive nucleophile, requiring entirely different pharmacologic strategies.
Given the superiority of divarasib over first-generation KRAS G12C inhibitors in this trial, how should clinicians integrate divarasib into the standard treatment algorithm for a patient with advanced KRAS G12C-mutated NSCLC who has just progressed on first-line platinum-doublet chemotherapy and pembrolizumab?
Key Response
Residents must understand treatment sequencing. Following progression on first-line chemoimmunotherapy, divarasib would now position itself as the preferred targeted agent in the second-line setting over sotorasib or adagrasib, provided the toxicity profile is acceptable, completely shifting the standard second-line approach away from older targeted therapies or docetaxel.
Acquired resistance to first-generation KRAS G12C inhibitors often involves secondary mutations (e.g., Y96D) or alternative pathway activation (e.g., EGFR, MET). How might the unique binding kinetics or pharmacokinetic profile of divarasib overcome these specific resistance mechanisms or improve central nervous system penetrance compared to sotorasib?
Key Response
Fellows need to grasp acquired resistance mechanisms in targeted therapies. If divarasib has a different binding footprint or higher potency, it might retain activity against certain secondary KRAS mutations (like Y96 or R68). Furthermore, differential blood-brain barrier penetration is a critical factor for selecting targeted therapies in advanced NSCLC with CNS metastases.
With divarasib establishing superiority in the monotherapy refractory setting, the next logical step is moving it to the frontline or combining it with checkpoint inhibitors. Given the prohibitive hepatotoxicity previously seen when combining sotorasib with immunotherapy, what specific pharmacological properties of divarasib might allow for safer frontline IO combinations?
Key Response
Attendings focus on future practice changes and toxicity management. Sotorasib combined with PD-(L)1 inhibitors yielded severe liver toxicity. If divarasib is more potent and highly selective with fewer off-target effects, it might allow for safer combination strategies in the frontline setting, which would upend current first-line chemo-IO standards for this subset.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
To definitively prove that divarasib's clinical superiority is driven by deeper target inhibition rather than just a more favorable pharmacokinetic profile, what correlative circulating tumor DNA (ctDNA) dynamics and single-cell sequencing analyses would be required during the early on-treatment phase?
Key Response
Researchers need to dissect the underlying molecular efficacy. Tracking variant allele fraction (VAF) clearance in ctDNA and using single-cell RNA/DNA sequencing of post-progression biopsies would delineate whether divarasib merely suppresses the primary G12C clone longer or actually prevents the emergence of distinct resistance subclones compared to first-generation drugs.
Considering this trial compares a next-generation inhibitor directly to first-generation inhibitors to assess overall survival (OS), what were the specific provisions for crossover upon progression, and how does this potential confounding affect the interpretation of the OS endpoint?
Key Response
Editors must scrutinize trial design for threats to validity. If patients on sotorasib/adagrasib were allowed to cross over to divarasib upon progression, a true OS benefit might be masked. Conversely, if crossover was prohibited, it raises ethical questions and might exaggerate the OS benefit if divarasib represents a highly active salvage therapy.
Based on the demonstrated overall survival benefit of divarasib over sotorasib and adagrasib, should current ASCO and NCCN guidelines be updated to grant divarasib a Category 1 preferred recommendation for second-line therapy in KRAS G12C-mutated NSCLC, and should the first-generation agents be entirely removed from the algorithms?
Key Response
Guideline committees evaluate whether a new drug completely replaces older ones. Currently, sotorasib and adagrasib are NCCN category 2A recommendations in the second-line setting post-chemo/IO. A direct randomized phase 3 trial showing superiority in both PFS and OS would elevate divarasib to Category 1 preferred status, potentially making first-generation agents obsolete in clinical guidelines.
Clinical Landscape
Noteworthy Related Trials
KRYSTAL-1 Trial
Tested
Adagrasib 600 mg twice daily
Population
Patients with KRAS G12C-mutated NSCLC previously treated with platinum-based chemotherapy and anti-PD-1/PD-L1 therapy
Comparator
None (Single-arm)
Endpoint
Objective response rate
CodeBreaK 200 Trial
Tested
Sotorasib 960 mg daily
Population
Previously treated patients with KRAS G12C-mutated advanced NSCLC
Comparator
Docetaxel
Endpoint
Progression-free survival
Divarasib Phase 1 Trial
Tested
Divarasib at varying doses
Population
Patients with advanced solid tumors harboring a KRAS G12C mutation
Comparator
None (Dose-escalation)
Endpoint
Safety and objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis